Gynecologic Cancers Hub

Gynecologic Cancers Hub

Videos

Brian Slomovitz shares the results of the innovaTV 301 trial of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.

News

The FDA has approved dostarlimab with carboplatin and paclitaxel for patients with dMMR or MSI-H endometrial cancer.
i3 Health provided an educational activity that challenged knowledge gaps regarding recurrent or metastatic cervical cancer.
The FDA has approved dostarlimab-gxly for treatment of mismatch repair–deficient recurrent or advanced endometrial cancer.
The FDA has approved mirvetuximab soravtansine for epithelial ovarian, fallopian tube, and primary peritoneal cancers.
In this interview, Ritu Salani discusses the importance of staying up to date with the evolving landscape of endometrial cancer treatment options.
b2ap3_large_1280px-Cytological_specimen_showing_cervical_cancer-compressed

Podcasts

Brian Slomovitz shares the results of the innovaTV 301 trial of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.
Kathleen Moore discusses her presentation regarding the results of the MIRASOL trial of mirvetuximab soravtansine for ovarian cancer.
Noelle Cloven discusses the ongoing ARTISTRY-7 trial studying nemvaleukin alfa for platinum-resistant ovarian cancers.